– USA, MA – Flare Therapeutics Inc., a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Jigar Raythatha, venture partner at Third Rock Ventures, to its Board of Directors.
About Jigar Raythatha
Jigar Raythatha, the venture partner with Third Rock Ventures, has joined the Board of Directors, bringing a wealth of expertise in precision oncology including previous leadership and board positions at Constellation Pharmaceuticals, Jounce Therapeutics, and Triana Biomedicines, among others.
About Flare Therapeutics Inc.
Flare Therapeutics is a biotechnology company changing the paradigm in drugging transcription factors with an initial focus on precision oncology. Flare’s proprietary engine is founded on the identification of novel druggable pockets, or ‘switch sites’, within transcription factor complexes that solve where to drug and how to tune gene expression to discover small molecule precision medicines for cancer and other diseases. The team has rapidly advanced an emerging pipeline of assets and plans to advance its lead precision oncology program, FX-909, a small molecule inhibitor targeting PPARG into the clinic in 2023 in individuals with locally advanced or metastatic urothelial cancer.
For more information: https://www.flaretx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.